Green Wesley, Lind John T, Sheybani Arsham
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in Saint Louis, Saint Louis, Missouri, USA.
Curr Opin Ophthalmol. 2018 Mar;29(2):162-170. doi: 10.1097/ICU.0000000000000462.
Two new translimbal glaucoma devices (Xen Gel Stent and InnFocus MicroShunt) have been developed with the goal of optimizing the predictability and safety for subconjunctival glaucoma surgery.
The new subconjunctival glaucoma implants are manufactured from nonsilicone, biocompatible materials, which may reduce the postoperative inflammatory and fibrotic reactions that can lead to failure. Early data suggests a favorable safety profile with significant reductions in intraocular pressure (IOP). The prevention of chronic hypotony has been a hallmark of the devices, which utilize an intrinsic flow-limiting design based on the tube length and internal lumen diameter.
Early data with the XEN Gel Stent and InnFocus MicroShunt show promising results. Prospective comparative studies comparing these devices with tube shunt and trabeculectomy will be needed.
已研发出两种新型经角膜缘青光眼装置（Xen凝胶支架和InnFocus微型分流器），旨在优化结膜下青光眼手术的可预测性和安全性。
新型结膜下青光眼植入物由非硅酮生物相容性材料制成，这可能减少可导致手术失败的术后炎症和纤维化反应。早期数据表明其安全性良好，眼压显著降低。预防慢性低眼压一直是这些装置的一个特点，它们采用基于管长和内腔直径的内在限流设计。
XEN凝胶支架和InnFocus微型分流器的早期数据显示出有前景的结果。需要进行将这些装置与管状分流术和小梁切除术进行比较的前瞻性对照研究。
